MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Zynerba Pharmaceuticals ROCE Ratio 2011-2025 | ZYNE
Annual ROCE Ratio Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -76.25 | -51.85 | -86.56 | -45.33 | -70.13 | -53.27 | -78.44 | -31.56 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -31.56 | -86.56 | -61.68 |
Quarterly ROCE Ratio Zynerba Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -97.44 | -75.09 | -45.78 | -58.76 | -55.63 | -50.83 | -32.43 | -49.37 | -51.75 | -76.85 | -86.56 | -84.72 | -71.92 | -50.83 | -45.4 | -44.27 | -55.58 | -61.13 | -70.13 | -69.63 | -69.79 | -62.73 | -53.85 | -62.98 | -69.23 | -76.74 | -78.44 | -69.49 | -59.28 | -42.14 | -31.56 | -0.48 | 40.82 | 63.66 | 67.42 | 49.98 | 18.75 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 67.42 | -97.44 | -45.14 |
ROCE Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-4.18 | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-176.47 | $ 0.73 | -3.6 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
267.43 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-24.04 | $ 1.7 | -2.59 % | $ 183 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-190.63 | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
3101.1 | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
-10.43 | $ 3.07 | -6.25 % | $ 1.6 B | Canada |
 |
Agile Therapeutics
AGRX
|
121.85 | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-23.09 | $ 5.11 | -5.46 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
-20.78 | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-39.6 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.61 | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-249.5 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
34.66 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
7.34 | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
-111.87 | $ 12.37 | 8.32 % | $ 633 M | USA |
 |
Evoke Pharma
EVOK
|
-184.26 | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
1076.15 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-57.41 | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
-623.16 | $ 7.18 | 1.99 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
0.61 | $ 46.29 | -1.64 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
-59.23 | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
-94.23 | $ 6.9 | -0.36 % | $ 2.52 B | Canada |
 |
Organogenesis Holdings
ORGO
|
-0.49 | $ 4.78 | -0.83 % | $ 629 M | USA |
 |
Lannett Company
LCI
|
70.21 | - | 1.15 % | $ 7.11 M | USA |
 |
Pacira BioSciences
PCRX
|
-9.43 | $ 26.61 | 1.22 % | $ 1.23 B | USA |
 |
OrganiGram Holdings
OGI
|
-35.84 | $ 1.8 | -6.19 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-8.06 | $ 3.11 | 22.92 % | $ 43.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-29.88 | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
-31.33 | $ 0.88 | -5.3 % | $ 20.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-84.11 | $ 3.55 | -1.11 % | $ 4.41 M | USA |
 |
Solid Biosciences
SLDB
|
-81.9 | $ 5.75 | -2.04 % | $ 235 M | USA |
 |
PetIQ
PETQ
|
5.46 | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-121.49 | $ 4.34 | 6.91 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
-116.71 | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
1.31 | $ 12.77 | -2.78 % | $ 1.75 B | USA |
 |
ProPhase Labs
PRPH
|
32.97 | $ 0.11 | -0.35 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
21.53 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-6.09 | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
-68.48 | $ 1.99 | -9.95 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-114.23 | $ 2.4 | -0.83 % | $ 324 M | USA |
 |
OptiNose
OPTN
|
26.27 | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-114.37 | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
-235.96 | $ 1.19 | -0.83 % | $ 5.13 M | USA |
 |
SCYNEXIS
SCYX
|
99.6 | $ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-70162.39 | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-41.31 | $ 11.01 | -9.4 % | $ 6.8 B | Canada |
 |
TherapeuticsMD
TXMD
|
-29.1 | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
-13.16 | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
7.66 | $ 11.68 | 0.29 % | $ 14.2 B | USA |